Skip to Content
Merck
CN

936421

Fmoc-Val-Ala-OH

≥95%

Synonym(s):

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-L-valyl-L-alanine, L-Alanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl-, L-Alanine, N-[N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-valyl]-

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C23H26N2O5
Molecular Weight:
410.46
UNSPSC Code:
12352106
NACRES:
NA.22
MDL number:
MFCD28387722

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

KQZMZNLKVKGMJS-XOBRGWDASA-N

SMILES string

C(OC(N[C@H](C(N[C@H](C(O)=O)C)=O)C(C)C)=O)C1C=2C(C=3C1=CC=CC3)=CC=CC2

InChI

1S/C26H32N4O6/c1-15(2)22(23(31)29-21(24(32)33)12-7-13-28-25(27)34)30-26(35)36-14-20-18-10-5-3-8-16(18)17-9-4-6-11-19(17)20/h3-6,8-11,15,20-22H,7,12-14H2,1-2H3,(H,29,31)(H,30,35)(H,32,33)(H3,27,28,34)/t21-,22-/m0/s1

assay

≥95%

form

powder or crystals

color

white to off-white

storage temp.

2-8°C

Quality Level

100

Application

Fmoc-Val-Ala-OH is a lysosomally cleavable linker used in construction of antibody-drug conjugates (ADC & Bioconjugation).

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000303192
0000303192
0000284819
0000284819

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Alain Beck et al.
Nature reviews. Drug discovery, 16(5), 315-337 (2017-03-18)
Antibody-drug conjugates (ADCs) are one of the fastest growing classes of oncology therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) and trastuzumab emtansine (in 2013) have paved the way for ongoing clinical trials that

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service